Currently, the most common endocrine therapy agents used in breast cancer include selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), selective estrogen receptor degraders (SERDs), and ovarian function suppression (OFS). This evidence concerns the gene ESR1 and breast carcinoma.